Romosozumab + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Osteopenia

Conditions

Osteopenia

Trial Timeline

Dec 13, 2006 → Jul 6, 2007

NCT ID

NCT01059435

About Romosozumab + Placebo

Romosozumab + Placebo is a phase 1 stage product being developed by Amgen for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT01059435. Target conditions include Osteopenia.

What happened to similar drugs?

5 of 10 similar drugs in Osteopenia were approved

Approved (5) Terminated (0) Active (5)

✅Teriparatide + Zoledronic AcidEli LillyApproved

✅alendronate sodiumMerckApproved

🔄zoledronic acidNovartisPhase 3

✅zoledronic acid vs pamidronateNovartisApproved

🔄Zoledronic Acid + PlaceboNovartisPhase 3

✅Placebo + ibandronate [Bonviva/Boniva]RocheApproved

🔄ibandronate [Bonviva/Boniva] + PlaceboRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02791516	Phase 3	Completed	Jan 16, 2017	Dec 21, 2018	Postmenopausal Osteoporosis
NCT02186171	Phase 3	Completed	Jun 16, 2014	Apr 20, 2016	Osteoporosis in Men
NCT01992159	Phase 2	Completed	Oct 12, 2012	Jun 17, 2015	Postmenopausal Osteoporosis (PMO)
NCT01101061	Phase 1	Completed	May 3, 2010	Nov 1, 2010	Osteopenia
NCT00907296	Phase 2	Completed	Sep 2, 2009	May 10, 2013	Fracture Healing
NCT00950950	Phase 1	Completed	Aug 18, 2009	Aug 19, 2010	Osteopenia
NCT01825785	Phase 1	Completed	Nov 14, 2007	Dec 2, 2008	Postmenopausal
NCT01059435	Phase 1	Completed	Dec 13, 2006	Jul 6, 2007	Osteopenia

Competing Products

18 competing products in Osteopenia

See all competitors

Product	Company	Stage	Hype Score
Teriparatide + Zoledronic Acid	Eli Lilly	Approved	43
alendronate sodium	Merck	Approved	43
zoledronic acid	Novartis	Phase 3	40
zoledronic acid vs pamidronate	Novartis	Approved	43
Zoledronic Acid + Placebo	Novartis	Phase 3	40
BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804	Novartis	Phase 2	35
Placebo + ibandronate [Bonviva/Boniva]	Roche	Approved	43
ibandronate [Bonviva/Boniva] + Placebo	Roche	Phase 3	40
Placebo + AMG 167	Amgen	Phase 1	29
AMG 167 + Placebo	Amgen	Phase 1	29
Romosozumab + Placebo	Amgen	Phase 1	29
Denosumab	Amgen	Phase 3	40
Romosozumab + Placebo	Amgen	Phase 1	29
Dasatinib 100 Mg Oral Tablet	Novo Nordisk	Phase 2	39
RN564	Pfizer	Phase 1	29
risedronate + alendronate	Sanofi	Phase 1	29
Menostar (Estradiol, BAY86-5435) + Raloxifene	Bayer	Phase 3	37
tibolone + raloxifen	Organon	Approved	37